瑞普生物
(300119)
| 流通市值：55.08亿 | | | 总市值：75.62亿 |
| 流通股本：3.39亿 | | | 总股本：4.65亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 2,670,506,885.08 | 1,720,460,367.77 | 826,126,074.24 | 3,398,458,452.83 |
| 营业总成本 | 2,328,498,364.54 | 1,487,878,552.08 | 704,661,498.03 | 3,020,087,411.56 |
| 其他经营收益 | | | | |
| 营业利润 | 376,030,534.89 | 240,058,886.22 | 128,605,155.19 | 479,584,919.95 |
| 利润总额 | 374,662,791 | 240,985,491.23 | 128,463,443.95 | 470,690,631.32 |
| 净利润 | 344,078,942.54 | 221,915,239.8 | 117,408,841.8 | 434,469,249.03 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | 45,528.73 |
| 综合收益总额 | 344,078,942.54 | 221,915,239.8 | 117,408,841.8 | 434,514,777.76 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 3,551,697,523.64 | 3,431,710,027.36 | 3,535,224,928.89 | 3,374,603,369.09 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,683,970,098.94 | 4,379,286,849.96 | 4,267,100,088.62 | 4,281,306,339.53 |
| 资产总计 | 8,235,667,622.58 | 7,810,996,877.32 | 7,802,325,017.51 | 7,655,909,708.62 |
| 流动负债: | | | | |
| 流动负债合计 | 2,338,472,556.31 | 2,124,225,340.88 | 1,958,380,391.59 | 1,889,607,060.9 |
| 非流动负债: | | | | |
| 非流动负债合计 | 593,039,061.13 | 562,726,773.63 | 572,295,322.64 | 581,679,198.83 |
| 负债合计 | 2,931,511,617.44 | 2,686,952,114.51 | 2,530,675,714.23 | 2,471,286,259.73 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,793,399,869.33 | 4,706,184,250.44 | 4,810,861,219.67 | 4,703,083,000.41 |
| 股东权益合计 | 5,304,156,005.14 | 5,124,044,762.81 | 5,271,649,303.28 | 5,184,623,448.89 |
| 负债和股东权益合计 | 8,235,667,622.58 | 7,810,996,877.32 | 7,802,325,017.51 | 7,655,909,708.62 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,708,897,511.97 | 1,682,209,981.13 | 761,602,097.67 | 3,503,825,792.52 |
| 经营活动现金流出小计 | 2,330,942,046.83 | 1,488,565,887.78 | 750,252,571.14 | 3,206,292,174.12 |
| 经营活动产生的现金流量净额 | 377,955,465.14 | 193,644,093.35 | 11,349,526.53 | 297,533,618.4 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,737,842,311.45 | 923,377,805.12 | 488,420,119.41 | 2,915,162,422.53 |
| 投资活动现金流出小计 | 2,165,220,672.24 | 1,140,950,392.73 | 641,646,806.27 | 2,812,937,992.05 |
| 投资活动产生的现金流量净额 | -427,378,360.79 | -217,572,587.61 | -153,226,686.86 | 102,224,430.48 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,147,362,140.03 | 833,186,155.57 | 175,498,061.65 | 1,194,901,963.01 |
| 筹资活动现金流出小计 | 1,316,907,193.6 | 907,606,080.88 | 116,425,634.46 | 1,445,368,104.29 |
| 筹资活动产生的现金流量净额 | -169,545,053.57 | -74,419,925.31 | 59,072,427.19 | -250,466,141.28 |
| 汇率变动对现金及现金等价物的影响 | -1,981,037.34 | -1,393,037.36 | -517,499.31 | -1,817.85 |
| 现金及现金等价物净增加额 | -220,948,986.56 | -99,741,456.93 | -83,322,232.45 | 149,290,089.75 |
| 期末现金及现金等价物余额 | 404,566,966.73 | 525,774,496.36 | 542,193,720.84 | 625,515,953.29 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -99,741,456.93 | - | 149,290,089.75 |
最新报告期：2026-10-28| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 财通证券 | 肖珮菁 | 0.94 | 1.11 | 1.34 | 2026-10-28 |
| 华泰证券 | 季珂,樊俊豪 | 0.86 | 1.12 | 1.46 | 2026-10-28 |
| 浙商证券 | 张心怡,钟凯锋 | 0.98 | 1.25 | 1.47 | 2026-08-31 |
| 中邮证券 | 王琦 | 0.93 | 1.10 | 1.30 | 2026-08-28 |
| 华泰证券 | 季珂,樊俊豪 | 1.01 | 1.32 | 1.69 | 2026-08-27 |